10-89225233-G-A
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000235.4(LIPA):c.539-5C>T variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.219 in 1,613,070 control chromosomes in the GnomAD database, including 48,404 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
NM_000235.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LIPA | NM_000235.4 | c.539-5C>T | splice_region_variant, intron_variant | ENST00000336233.10 | NP_000226.2 | |||
LIPA | NM_001127605.3 | c.539-5C>T | splice_region_variant, intron_variant | NP_001121077.1 | ||||
LIPA | NM_001288979.2 | c.191-5C>T | splice_region_variant, intron_variant | NP_001275908.1 | ||||
LIPA | XM_024448023.2 | c.539-5C>T | splice_region_variant, intron_variant | XP_024303791.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LIPA | ENST00000336233.10 | c.539-5C>T | splice_region_variant, intron_variant | 1 | NM_000235.4 | ENSP00000337354.5 |
Frequencies
GnomAD3 genomes AF: 0.209 AC: 31723AN: 152006Hom.: 4533 Cov.: 32
GnomAD3 exomes AF: 0.289 AC: 72636AN: 251068Hom.: 14075 AF XY: 0.282 AC XY: 38316AN XY: 135730
GnomAD4 exome AF: 0.220 AC: 321511AN: 1460946Hom.: 43864 Cov.: 34 AF XY: 0.222 AC XY: 161564AN XY: 726822
GnomAD4 genome AF: 0.209 AC: 31753AN: 152124Hom.: 4540 Cov.: 32 AF XY: 0.218 AC XY: 16200AN XY: 74358
ClinVar
Submissions by phenotype
Lysosomal acid lipase deficiency Benign:4
Benign, criteria provided, single submitter | clinical testing | GENinCode PLC | Jul 06, 2022 | - - |
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Nov 20, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 10, 2021 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2015 | - - |
Benign, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 26, 2015 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Wolman disease Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 11, 2018 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at